الفهرس 
FEMALE INFERTILITYOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Background Polycystic ovary syndrome (pco) is the major cause of an ovulatory infertility. Clomiphene citrate (cc) is the most commonly used oral agent for ovulation induction in this group. But there are some drawbacks with the use of it.
Clomiphene citrate resistance occur in 15-20% of patients and is not predictable before beginning the treatment.
Letrozole a non steroidal aromatase inhibitor has been introduced as a new treatment option which can challenge clomiphene citrate for ovulation induction in anovulatory women.
Considering ovulation and pregnancy rate letrolozole is at least an effective as (CC) in (PCO) with additional advantage including reduced risk of multiple pregnancy and ovarian hyper stimulation syndrome, absence of deleterious effect on cervical mucus and endometrial development and need for less monitoring during ovarian stimulation.
However with the development of human chorionic gonadotropin (HCG) and its application to trigger ovulation and time insemination, controversy has arisen as to the best method of timing intercourse to achieve optimal pregnancy rate.
objective of this study was to investigate the effect of low dose and high dose of letrozole on ovulation induction and effect of spontaneous & timed intercourse with (HCG) on pregnancy rate.
Method This four arm clinical randomized trial study was carried out at Ain Shams Maternity Hospital Infertility Clinic And Qena General Hospital Infertility clinic. The current study was conducted on 136 women. group A = letrozole 2.5 mg without HCG. group B = letrozole 2.5 mg+ HCG 10.000 IU. group C = letrozole 10 mg without HCG. group D = lertozole 10 mg + HCG 10.000 IU. Start from 4 October 2021 ended 10 Jon 2023.